Veteran Global Health Leader, Dr. Rebecca Martin, Named President of Global Immunization at Sabin
Martin most recently served as Vice President for Global Health at Emory University, and as the Director of the Emory Global Health Institute, following a 24-year career with the US Centers for Disease Control and Prevention (CDC). She is also an adjunct professor in the Department of Global Health at Emory. She brings decades of successful partnering with global, regional and country-level health leaders in infectious disease prevention, as well as in-country experience leading low- and middle-income country (LMIC) health and immunization initiatives.
Her extensive CDC career includes ten years working in Kenya, Tanzania, and Denmark, seconded to the World Health Organization African and European regions. In her four years in Nairobi, Kenya, she provided technical expertise to eight East African countries focused on vaccine-preventable disease surveillance, prevention and elimination strategies and policies, and new vaccine introductions. For several years in Dar as Salaam, Tanzania, she led surveillance and workforce development for CDC as part of the President's Emergency Plan for AIDS Relief (PEPFAR), and supervised staff in surveillance, health management information systems (HMIS), monitoring and evaluation (M&E), and human capacity development for CDC HIV/AIDS programs.
Currently, she serves as the Vice-Chair for WHO Regional Office for Africa (AFRO) Emergency Preparedness & Response Technical Advisory Group (EPR-TAG), an independent advisory group providing strategic guidance on all matters pertaining to public health emergency preparedness and response in Africa.
'With her global, country and local-level experience, Rebecca has the first-hand expertise needed to address today's challenging immunization landscape, and more importantly, to co-create new solutions with public and private partners to boost lagging immunization rates and prevent human suffering,' says Sabin CEO Amy Finan. 'She is an outstanding addition to Sabin's executive team and will lead Sabin's global immunization work as we continue to respond to the needs of individual countries and help shape new global strategies with partners to increase access and uptake of vaccines.'
Martin calls her new role a 'full circle' moment.
'I am honored and excited to join the Sabin Vaccine Institute as President of Global Immunization, bringing my experience, knowledge, and commitment to Sabin's critical mission in making vaccines available to everyone, everywhere,' she says.
'I am thrilled to work with the dedicated colleagues at Sabin who are passionate about tackling vaccine-preventable diseases through collaboration with stakeholders from multiple sectors in addition to health,' she adds. 'There is no moment more urgent than now to innovate and double down on our efforts to prevent illness and save lives through immunization.'
Sabin's Global Immunization team works with local and national governments and academic, global, and philanthropic partners to put communities at the heart of solutions that tackle urgent vaccination challenges, with a renewed focus to bolster the falling coverage in childhood routine immunization and support life-course immunization. In 2023, almost 14.5 million children received no vaccinations, according to WHO, an increase of 2.7 million more children compared to 2019.
The Sabin team brings expertise across the immunization spectrum, including building global communities of practice, identifying barriers and creating solutions to improve vaccine access and delivery of current and new vaccines, and conducting epidemiological research to support immunization. Sabin's skills are applied to multiple infectious diseases, including HPV, typhoid, cholera, rotavirus, COVID-19 and malaria. Additional work includes efforts to immunize zero-dose children and transition to hexavalent vaccines in national immunization programs.
During her tenure at Emory, Martin built and aligned multidisciplinary global health infrastructure, fostered global collaborations across health organizations, led interdisciplinary global health research and worked to build the next generation of global health leaders. She was also a member of Emory's Woodruff Health Sciences Center leadership team.
Martin's most recent role with the CDC was Director of the Center for Global Health, then the largest operating unit at the CDC. Her achievements include leading the CDC's global efforts across disease initiatives and through the start of the global health security agenda, including polio eradication and disease control acceleration and elimination for vaccine-preventable diseases, malaria elimination, ending HV epidemics, and strengthening health systems to detect and respond to disease threats and emergencies.
Martin received her Doctor of Philosophy from the Johns Hopkins Bloomberg School of Public Health in international health with a focus on infectious disease epidemiology. She has co-authored manuscripts and developed strategic plans, normative guidance and guidelines on immunization strategies, vaccine-preventable diseases and surveillance methods for both immunization and HIV, and for global health security.
About the Sabin Vaccine Institute
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a nonprofit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit
www.sabin.org
and follow us on X @SabinVaccine.
Media Contact:
Monika Guttman
Senior Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 621-1691
press@sabin.org
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/05fb30d1-3f58-4240-aafe-91d33dab3398
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Why Is Catheter Precision Stock (VTAK) Up 70% Today?
Catheter Precision (VTAK) stock saw major gains on Monday after the medical device company's LockeT was registered and approved in the UK. This was the final step needed to begin sales of the suture retention device in the UK after it received a CE Mark for European approval and distribution in May 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Catheter Precision will sell LockeT through UK-based value-added distributor HC21. The company has already worked with this distributor for years, selling other products in the region. This agreement was updated to include sales of LockeT. Fatih Ayoglu, Catheter Precision Sales Manager EMEA & APAC, said, 'We are proud to announce the approval of LockeT for use in the United Kingdom, marking a significant milestone in our mission to support healthcare systems with innovative, patient-centric solutions. With the NHS recently achieving its first reduction in waiting lists in 17 years, LockeT is poised to contribute meaningfully to this momentum by helping clinicians deliver more treatments, more efficiently.' Catheter Precision Stock Movement Today Catheter Precision stock was up 72.03% in pre-market trading on Monday, following a 10.74% fall on Friday. The company's shares have also declined 69.54% year-to-date and 93.78% over the past 12 months. Today's movement came with heavy trading, as some 23 million shares changed hands, compared to a three-month daily average of about 92,000 units. Is Catheter Precision Stock a Buy, Sell, or Hold? Turning to Wall Street, coverage of Catheter Precision stock is thin. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates VTAK stock a Neutral (41) with no price target. It cites 'significant financial and operational challenges with ongoing losses and negative cash flow' as reasons for this stance.
6 hours ago
Leading pediatrician group recommends COVID vaccine for infants, toddlers in contrast with RFK Jr.
The American Academy of Pediatrics (AAP) said on Tuesday that children ages 6 months to 23 months should receive a COVID-19 vaccine, in contrast with federal health officials. The recommendations are part of the AAP's annual childhood immunization schedule, which includes guidance for COVID, flu and RSV vaccines for those aged 18 and younger. The AAP has been releasing its own recommendations since the 1930s, but in a rare occurrence, the recommendations differ from those put out by the Centers for Disease Control and Prevention (CDC). The group also recommended Americans age 18 and under receive a COVID vaccine if they are at high risk of severe COVID, live in a long-term care facility or congregate setting, if they have never been vaccinated against COVID or if they live with someone at high risk for severe COVID. It comes after Health and Human Services secretary Robert F. Kennedy Jr. announced in late May that the CDC would no longer recommend the COVID vaccine for healthy children. The CDC, which is under Kennedy's purview, later updated the guidance to a " shared clinical decision making" model -- leaving the decision to vaccinate children to parents alongside advice from a doctor. The prior recommendations were that everyone aged 6 months and older get vaccinated against COVID with the most up-to-date shot. The contrasting vaccine recommendations highlight the growing rift between federal health officials and medical organizations on vaccine policy. "The academy has been making pediatric immunization recommendations since the 1930s, that has not changed," Dr. Susan J. Kressly, president of the AAP, told ABC News. "But what has changed is that this year, we're doing it in the environment of misinformation, which makes it more important than ever that we provide clear and confident guidance, because the majority of American families really depend on us for this guidance." Children between 6 months old and 23 months old are at the highest risk of severe COVID-19, and the vaccine can protect against serious illness, according to the AAP. "We know that this age group, that's the highest risk for severe disease," Kressly said. "And so we want to make sure that those children who are at highest risk and did not live through the pandemic -- they were not exposed to COVID viruses during the pandemic -- we want to make sure that they are protected as best as possible." Although medical organizations may differ in their vaccine recommendations, insurers often rely on the CDC's vaccine panel, known as the Advisory Committee on Immunization Practices (ACIP), recommendations to determine what they will and won't cover. If certain vaccines aren't recommended by the ACIP, it may lead to parents or guardians facing out-of-pocket costs if their children receive the shot. It could also mean the shots aren't covered by the Vaccines for Children (VFC) program, a federally funded program that provides no-cost vaccines to eligible children. "We need to work with our like-minded policy makers who understand the importance of keeping VFC vaccines available in every community for those children who depend on them," Kressly said. "At the same time, there are children in this country whose vaccines are paid for through commercial insurance, and we are having continuing conversations with major payers to make sure that those can be vaccines are available as well. Vaccination is part of high-quality preventive care, and we are confident that we can work with the payers to make sure that translated into policy."
Scientific American
8 hours ago
- Scientific American
More Teens Are Getting Vaccines
U.S. teenagers are rebelling. More teens got recommended vaccinations in 2024 than did so in 2023. This trend is the opposite of what's happening in younger children: vaccine rates in the U.S. continue to fall among kids who are entering kindergarten. The numbers come from the most recent report on childhood vaccinations from the Centers for Disease Control and Prevention. The uptick among teens is a win for public health as the vaccine framework in the U.S. is under attack. Robert F. Kennedy, Jr., head of the Department of Health and Human Services, has placed antivaccine advocates on the CDC's advisory committee that makes vaccine recommendations. The federal government has ended grants for the development of mRNA vaccines despite the safety and success of COVID shots. Since January there have been 32 measles outbreaks, largely among children and teens that did not get measles shots. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. But the new findings suggest that communication between providers and parents can lead to higher vaccine uptake. In 2024 the percentage of teens aged 13 to 17 who got two or more doses of the combination measles, mumps and rubella (MMR) shot increased from the portion in 2023, from 91.3 percent to 92.6 percent. The percentage of teens who got the combination tetanus, diphtheria and pertussis (Tdap) vaccine rose from 89 percent in 2023 to 91.3 percent last year. And the number of teens who got at least one dose of the four-pronged meningococcal ACWY (MenACWY) shot increased from 88.4 percent in 2023 to 90.1 percent in 2024. (The MenACWY vaccine spurs an immune response to four versions of a bacteria that causes meningitis.) The results were published last Friday in the CDC's Morbidity and Mortality Weekly Report. The authors analyzed data collected from the 2024 National Immunization Survey–Teen, a two-phase survey that asked parents and their children's providers about vaccine use. But not all of the trends were upward. In 2024, for the third year in a row, teens' uptake of the HPV vaccine—which protects against the cancer-causing human papillomavirus—remained the same. The national average of teens who have had at least one dose of the HPV vaccine held steady at 78 percent, though there was broad variability from state to state. The researchers reported that, in 2024, less than 40 percent of teens in Mississippi got at least one shot, but close to 80 percent in Massachusetts did so. And communication was key: parents who reported talking about the vaccine with a provider were more likely to have teens who got it. In metropolitan statistical areas (which can include urban, suburban and rural communities), the percentage of teens who got the vaccine was about 18.8 percentage points higher on average when their provider recommended it than when the provider didn't. And in addition to variability among states, there were other differences. In general, urban areas had higher vaccination rates than rural areas and, in some cases, suburban ones. This sort of difference has long been the case in the U.S., where transportation, insurance coverage and provider availability have created wide rural-urban disparities in health care access. For some of the diseases targeted by the vaccines on the CDC's immunization schedule, even the increase in teens getting the shots doesn't mean the U.S. is at a herd immunity level, the point at which the population as a whole is more generally protected from an illness. For example, to achieve herd immunity for pertussis, 92 to 94 percent of the population needs to be vaccinated. The vaccination rate for kindergartners in 2024–2025 was 92.1 percent. Teens were at 91.3 percent, putting the U.S. just under the lower threshold for herd immunity. In 2024 there were more than 35,000 cases of whooping cough in the U.S. In 2023 there were approximately 7,000.
